Preticks
.
Follow Us
News Details
Vanda Pharmaceuticals Announces Agreement with FDA on Resubmission of the Application for HETLIOZĀ® for the Treatment of Patients with Smith-Magenis Syndrome
About Vanda Pharmaceuticals Inc.
NASDAQ: $VNDA
Notified: $11.38
07:01 EDT
Price Chart